Skip to content

Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging

Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01451255
Enrollment
90
Registered
2011-10-13
Start date
2011-08-31
Completion date
2014-06-30
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension, Pulmonary Hypertension

Keywords

pulsatility, normal subjects, mild pulmonary hypertension, exercise-associated pulmonary hypertension

Brief summary

Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness. In addition, cardiac MRI could play provide early and effective treatment for Pulmonary Arterial Hypertension (PAH).

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

Consecutive patients aged ≥ 18 years with PAH as dictated by a comprehensive examination and echocardiography will be included for enrollment.

Exclusion criteria

* Age \< 18 years * Pregnancy * Mechanical ventilation * Acute or chronic renal failure (creatinine clearance \< 30 ml/min or requiring renal replacement therapy) * Inability to perform MRI (i.e. claustrophobia, severe obesity (\> 150 kg), device incompatible with MRI) * Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths) * Prior heart or lung transplantation * Left ventricular systolic (ejection fraction \< 50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction) * Significant left-sided valvular disease (≥ moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026